Introduction {#s1}
============

Viruses are exquisitely adapted to interact with host-cell machinery to facilitate their replication. Despite significant differences in this machinery across host species, some viruses like influenza can evolve to infect divergent hosts ([@bib64]; [@bib88]). Such zoonotic transmissions can have severe public health consequences: transmission of influenza virus from birds or pigs to humans has resulted in four pandemics over the last century ([@bib82]). These pandemics require the virus to adapt to the new host ([@bib52]). Delineating how viruses adapt to new hosts will aid in our ability to understand what determines if a chance zoonotic infection evolves into a human pandemic.

One critical determinant of influenza host range is the viral polymerase ([@bib52]), which transcribes and replicates the viral genome ([@bib23]; [@bib84]). Avian influenza polymerases perform poorly in mammalian cells ([@bib13]; [@bib53]; [@bib55]; [@bib61]). This host range restriction likely arises from the need for the viral polymerase to interact with host proteins such as importin-α ([@bib71]) and ANP32A ([@bib51]), which differ between avian and mammalian hosts. However, it remains unclear exactly how the molecular interfaces between the polymerase and these host proteins are altered during adaptation to humans ([@bib52]).

Studies of natural zoonoses and experimental passaging of viruses in the lab have identified a number of mutations that adapt avian influenza polymerases to mammalian hosts ([@bib11]; [@bib13]; [@bib12]; [@bib14]; [@bib24]; [@bib27]; [@bib41]; [@bib40]; [@bib45]; [@bib54]; [@bib57]; [@bib58]; [@bib59]; [@bib61]; [@bib69]; [@bib78]; [@bib79]; [@bib92]; [@bib93]). The best known of these mutations is E627K in the PB2 subunit of the polymerase ([@bib77]). This mutation alone significantly improves avian influenza polymerase activity in mammalian cells ([@bib50]; [@bib55]; [@bib56]; [@bib61]), and was considered a key step in adaptation to humans ([@bib81]). But surprisingly, the recent 2009 H1N1 pandemic lineage lacks the E627K mutation. Instead, it has acquired mutations to PB2 at sites 590 and 591 that similarly confer improved polymerase activity ([@bib57]; [@bib92]). This fact underscores the possibility that natural evolution has explored only a small fraction of the possible host-adaptation mutations. Examining only the currently available instances of adaptation in nature or the lab may therefore overlook additional mechanisms of adaptation and evolutionary paths to future zoonoses.

Here, we map all single amino-acid mutations to an avian influenza PB2 protein that enhance growth in human cells versus avian cells. We do so by leveraging deep mutational scanning ([@bib10]; [@bib25]), which previously has only been used to measure the functional effects of mutations to several influenza proteins in mammalian cells ([@bib1]; [@bib5]; [@bib21]; [@bib22]; [@bib43]; [@bib47]; [@bib89]; [@bib90]). We show that comparative deep mutational scanning in human versus avian cells identifies numerous human-adaptive mutations that have never before been described. These mutations cluster on the surface of the PB2 protein, highlighting potential interfaces with host factors. Some of these mutations are enriched in avian-human transmission of H7N9 influenza, demonstrating the utility of our experiments for anticipating PB2's adaptation in nature. The human-adaptive mutations that have not been observed in nature are often inaccessible by single-nucleotide mutations. Overall, our complete map of human-adaptive mutations sheds light on how species-specific selection and evolutionary accessibility shape influenza virus's evolution to new hosts.

Results {#s2}
=======

Deep mutational scanning of an avian influenza PB2 {#s2-1}
--------------------------------------------------

To identify host-adaptation mutations in PB2, we used deep mutational scanning to measure the effects of all amino-acid mutations to this protein in both human and avian cells. We performed these experiments using the PB2 from an avian influenza strain, A/Green-winged Teal/Ohio/175/1986 (also previously referred to as S009) ([@bib42]; [@bib57]). The PB2 from this strain is representative of avian influenza PB2s, most of which are highly similar (average pairwise amino-acid identity of 98.7%) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We mutagenized all codons in PB2 to create three replicate mutant plasmid libraries with an average of 1.4 codon substitutions per clone ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2A--F](#fig1s2){ref-type="fig"}). Since there are 759 residues in PB2, there are 759 × 19 = 14,421 amino acid mutations, virtually all of which are represented in our libraries ([Figure 1---figure supplement 2G](#fig1s2){ref-type="fig"}).

![Deep mutational scanning of avian influenza PB2 in human and avian cells.\
(**A**) We mutagenized all codons of PB2 from an avian influenza strain. We generated mutant virus libraries using a helper-virus approach, and passaged libraries at low MOI in human (A549) or duck (CCL-141) cells to select for functional PB2 variants. (**B**) We deep sequenced PB2 mutants from the initial mutant plasmid library and the mutant virus library after passage through each cell type. We computed the 'preference' for each amino acid in each cell type by comparing the frequency of each mutation before and after selection. In the logo plots, the height of each letter is proportional to the preference for that amino acid at that site. (**C**) To identify mutations that are adaptive in one cell type versus the other, we computed the differential selection by comparing the frequency of each amino-acid mutation in human versus avian cells. Letter heights are proportional to the log enrichment of the mutation in human versus avian cells. [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} shows the phylogenetic relation of the chosen avian influenza strain to other influenza strains. [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} shows further details of deep mutation scanning experiment. [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"} shows relative amplification of full-length PB2 versus PB2-GFP and PB2-deletion gene segments.](elife-45079-fig1){#fig1}

We generated a mutant virus library from each of the triplicate plasmid mutant libraries using a helper-virus approach, which reduces bottlenecks during generation of complex viral libraries ([@bib21]) ([Figure 1A](#fig1){ref-type="fig"}). For biosafety reasons, we rescued reassortant virus using polymerase (PB2, PB1, PA) and nucleoprotein (NP) genes from the avian influenza strain and the remaining viral genes (HA, NA, M, NS) from the lab-adapted A/WSN/1933(H1N1) mammalian influenza strain. We wanted to minimize selection for host-adaptive mutations during the initial library generation. Therefore, we generated the libraries in human HEK293T cells with a co-transfected protein-expression plasmid encoding the human-adapted PB2-E627K protein variant, so that all cells had a PB2 protein that could complement poorly functioning library variants.

To select for functional PB2 variants in human versus avian cells, we passaged each replicate mutant virus library at low MOI in the A549 human lung epithelial carcinoma line and CCL-141 duck embryonic fibroblasts ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). To quantify the functional selection on each mutation during viral growth, we deep sequenced the initial plasmid mutant libraries and the passaged mutant viruses to measure the frequency of mutations before and after selection ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). All experiments were also performed in parallel on virus carrying wild-type PB2 as a control to quantify the rate of errors arising during sequencing, library preparation, and viral replication ([Figure 1---figure supplement 2H](#fig1s2){ref-type="fig"}).

To assess the efficacy of selection without the complication of errors arising from sequencing and passaging, we examined the post-selection frequency of stop and nonsynonymous mutations accessible by \>1 nucleotide substitution. Stop and nonsynonymous mutations fell to 2--7% and 26--35% of their initial frequencies respectively ([Figure 1---figure supplement 2H](#fig1s2){ref-type="fig"}). In contrast, synonymous mutations remained at 68--87% of their initial frequency. Therefore, the experiments effectively selected for functional PB2 mutants.

We quantified selection at the amino-acid level in terms of the 'preference' of each site in the protein for each amino acid ([Figure 1B](#fig1){ref-type="fig"}) ([@bib6]). The preference for an amino acid is proportional to its enrichment during functional selection. We assessed the reproducibility of our experiments across biological replicates by examining the correlations of preferences for all 14,421 amino acid ([Figure 1---figure supplement 2I](#fig1s2){ref-type="fig"}). Biological replicates passaged in each cell type were well correlated (Pearson's *R* in human cells was 0.74 to 0.79; Pearson's *R* in avian cells was 0.76 to 0.79), and were generally better correlated within cell types than between cell types (Pearson's *R* between cell types was 0.67 to 0.78). For downstream analyses, we rescaled our preferences to match the stringency of selection in nature (see Materials and methods, [Supplementary file 4](#supp4){ref-type="supplementary-material"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}).

Experimental measurements are consistent with natural selection and known functional constraints on PB2 {#s2-2}
-------------------------------------------------------------------------------------------------------

Our experiments reflect known functional constraints on PB2 ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). As expected, the start codon shows a strong preference for methionine in both human and avian cells. PB2's cap-binding function is mediated by a hydrophobic cluster of five phenyalanines (F404, F323, F325, F330, F363), H357, E361, and K376 ([@bib35]). Phenylalanines are strongly preferred in the hydrophobic cluster in both host cell types, with the exception of site 323, which also tolerates aliphatic hydrophobic residues in human cells ([Figure 2A](#fig2){ref-type="fig"}). E361 is also strongly preferred in both cell types, as is K376 in the duck cells. A number of other amino acids are tolerated at site 376 in human cells, and at site 357 in both cell types. At site 357, aromatic residues tyrosine, tryptophan, and phenylalanine are preferred in addition to histidine, consistent with previous observations that the H357W substitution enhances binding to the m^7^GTP base ([@bib35]). Finally, the two motifs comprising the C-terminal bipartitite nuclear import signal, 736-KRKR-739 and 752-KRIR-755 ([@bib80]), are strongly and similarly preferred in both host cell types. Thus, our experimentally measured preferences largely agree with what is known about PB2 structure and function, and further suggest that functional constraints at these critical sites are similar in both human and avian cells.

![Functional constraints on PB2.\
(**A**) The amino acid preferences measured in human and avian cells for key regions of PB2: the start codon, sites involved in cap-binding, and sites comprising the nuclear localization sequence (NLS). The height of each letter is proportional to the preference for that amino acid at that site. Known critical amino acids are generally strongly preferred in both cell types. (**B**) Correlation of the site entropy of the amino-acid preferences measured in each cell type. (**C**) Sites of high variability (as measured by entropy) in natural human influenza sequences occur at sites of high entropy as experimentally measured in human cells. (**D**) Sites with high variability in natural avian influenza sequences occur at sites of high entropy as experimentally measured in duck cells. [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} shows the complete map of amino acid preferences as measured in human and avian cells. Preferences (as well as mutation effect and differential selection for all mutations as calculated for [Figure 3](#fig3){ref-type="fig"}) are in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.45079.009Figure 2---source data 1.Preference, mutation effect, and differential selection results for all mutations.](elife-45079-fig2){#fig2}

To more broadly investigate whether functional constraints are similar between both cell types across the entire PB2 protein, we computed the entropy of the amino acid preferences at each site. A larger site entropy indicates a higher tolerance for mutations at that site. Site entropies are well correlated between cell types ([Figure 2B](#fig2){ref-type="fig"}, *R* = 0.78), indicating that sites are usually under similar functional constraint in both cell types. These protein-wide measures of mutational tolerance are also consistent with natural sequence variation. Natural variation is generally low in natural avian sequences, probably because influenza A virus is highly adapted to avian hosts so there is little pressure for additional adaptation. Natural variation is generally higher in natural human sequences, likely because of increased genetic diversity generated as a result of directional selection to adapt to the human host ([@bib18]), and diversifying selection to escape immune selection on PB2-derived T-cell epitopes ([@bib2]). Sites that are highly variable among publicly available natural influenza sequences tend to also be ones that we experimentally measured to be mutationally tolerant ([Figure 2C,D](#fig2){ref-type="fig"}).

Identification of human-adaptive mutations {#s2-3}
------------------------------------------

To identify mutations that are adaptive in human versus avian cells, we quantified the host-specific effect of each mutation using two different metrics. The first metric, differential selection, quantifies how much a mutation is selected in one condition versus another ([@bib20]). Differential selection is computed by taking the logarithm of the relative enrichment of the mutation relative to the wild-type residue in human versus avian cells ([Figure 1C](#fig1){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Differential selection greater than zero indicates that a mutation is relatively more favorable in human than avian cells.

To test if differential selection accurately identifies host-specific mutations, we asked if a set of 25 previously experimentally verified human- or mammalian-adaptive mutations ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}) have differential selection values greater than zero. Indeed, most of these previously characterized mutations had positive differential selection values, as expected for human-adaptive mutations ([Figure 3A](#fig3){ref-type="fig"}). In contrast, all other mutations have a distribution of differential selection values centered around zero.

![Deep mutational scanning identifies known and novel host-adaptive mutations.\
(**A**) Distribution of experimentally measured differential selection for previously characterized human adaptive mutations and all other possible mutations to PB2. Positive differential selection means a mutation is favored in human versus avian cells. (**B**) Scatterplot of each mutation's effect in human versus avian cells, showing the top adaptive mutations identified in the deep mutational scanning. (**C**) Logoplots showing the differential selection at the sites of mutations that we chose for functional validation. The height of each letter above the line indicates how strongly it was selected in human versus avian cells. Top adaptive mutations are colored in orange (human-adaptive) or green (avian-adaptive). Mutations chosen for functional validation are indicated by an asterisk(\*). Additional mutations chosen for validation are colored light orange (differentially selected in human) or light green (differentially selected in bird). Mutations observed in H7N9 avian-to-human transmission are indicated by \#. Note that not all mutations with high differential selection in human versus avian cells are classified as top adaptive mutations because we also filtered for mutations that are substantially beneficial relative to wildtype. (**D**) Logoplots showing amino acid preferences at sites we chose for functional validation. Top mutations beneficial in both human and avian cells are colored purple. Mutations chosen for validation are indicated by \*. [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} shows the complete map of differential selection in human versus avian cells. Catalog of previously described human/mammalian adaptive mutations are in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.45079.012Figure 3---source data 1.Catalog of previously described human/mammalian adaptive mutations.](elife-45079-fig3){#fig3}

However, there are many previously uncharacterized mutations that have differential selection values similar to or greater than those of known human-adaptive mutations ([Figure 3A](#fig3){ref-type="fig"}). Of course, differential selection only quantifies the extent to which a mutation is more beneficial in human than avian cells. But importantly, for a mutation to be truly adaptive, it must also be more beneficial than the wild-type amino acid in human cells. To quantify each mutation's effect relative to wild type in each cell type, we computed the logarithm of the ratio of preferences of the mutant versus wild-type amino acid ([Figure 3B](#fig3){ref-type="fig"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Mutation effect values greater than zero indicate that a mutation is more preferred than the wild-type residue.

We identified top experimentally adaptive mutations using both differential selection and mutation effect metrics ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). We focused on the 34 mutations most adaptive in our human cell selection (differential selection \>1.5 and mutational effect in human cells \> 1). Among these 34 mutations, only one (D701N) has already been described as human adaptive. The E627K mutation is favored in human cells in our experiments, though it is not in this set of top 34 mutations. However, two other mutations at this site (E627C and E627S) are among the top 34 mutations ([Figure 3C](#fig3){ref-type="fig"}). S627 is naturally encoded by bat influenza and, in the context of bat influenza polymerase, supports high polymerase activity in human cells ([@bib86]; [@bib85]). In fact, it appears that many mutations at site 627 are human adaptive, with the exception of E627D. These observations are consistent with prior findings that a wide range of amino acid residues can be accommodated at site 627, and in fact improve polymerase activity in human HEK293T cells over the consensus avian wild-type glutamic acid ([@bib15]). We additionally identified 42 mutations as adaptive in avian cells (differential selection \<-2 and mutational effect in avian cells \> 1), and seven mutations that are more favorable than the wild-type amino acid in both cell types (mutational effect \>1 in both human and avian cells).

From these top adaptive mutations identified in our deep mutational scanning, we chose 26 for experimental validation. Specifically, we chose 18, four, and three mutations adaptive in human, avian, or both cell types, respectively ([Figure 3C,D](#fig3){ref-type="fig"}). We prioritized mutations that had consistent measurements across biological replicates. When there were multiple strongly adaptive mutations at a site, we chose just one mutation at that site to test mutations across more sites. Finally, we also validated additional mutations of particular interest, such as the only mutation at site 627 (E627D) that appeared to be favored in avian over human cells (negative differential selection), and mutations observed in avian-to-human transmission of H7N9 influenza (see below for more details).

Human-adaptive mutations identified in deep mutational scanning improve polymerase activity and viral growth in human cells {#s2-4}
---------------------------------------------------------------------------------------------------------------------------

The main function of the influenza polymerase is to transcribe and replicate the viral genome. We quantified the effect of mutations on polymerase activity using a minigenome assay which measures transcription of an engineered viral RNA encoding GFP by reconstituted influenza polymerase. To test whether the results of our deep mutational scanning are generalizable to human cells beyond the A549 cell line used in the scanning, we performed the minigenome polymerase activity assay in HEK293T as well as A549 cells.

Almost all the putative human-adaptive mutations identified in the deep mutational scanning improved transcriptional activity in human cells relative to the wild type or a synonymous mutant ([Figure 4A,B](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). Mutations that did not improve transcriptional activity retained at least wild-type activity. The effect of mutations in both human cell lines were remarkably consistent, suggesting that our deep mutational scanning yielded results that generalize across human cells.

![Validation of top experimentally adaptive mutations.\
The polymerase activity of selected PB2 mutants as measured using minigenome assays in A549 (**A**) and HEK293T (**B**) human cells. The mutations chosen for characterization include previously known human adaptive mutations, top adaptive mutations identified by our deep mutational scanning (orange = human adaptive, green = avian adaptive), and additional mutations differentially selected in human (light orange) or avian (light green) cells. E627E is a synonymous mutation at site 627 used as a negative control. Minigenome activity is represented as percent of transfected cells that expressed a viral GFP reporter. The gray horizontal line indicates the mean value measured for the wild type avian PB2. Minigenome assays were performed in biological triplicate. Mutations that have significantly different minigenome activity from wild type are indicated by asterisks (unpaired t-test, p\<0.05). (**C**) Competition of virus bearing the indicated mutant PB2 against virus with wild-type PB2. For each competition, human A549 and avian CCL-141 cells were infected with mutant and wild-type viruses mixed at a 1:1 ratio of transcriptionally active particles, and the frequency of each variant after viral replication was measured by deep sequencing viral RNA. For samples collected at 10 hr post infection, we infected cells at MOI of 0.1, and sequenced vRNA from cellular extract. For samples collected at 48 hr post infection, we infected cells at MOI of 0.01, and sequenced vRNA from the supernatant. The plots show the ratio of the mutant over wild-type variant in A549, divided by the same ratio in CCL-141 cells. A ratio \>1 indicates that a viral mutant grows better in human than avian cells. Competition assays were performed in biological duplicate; circle and cross represent replicate experiments. Flow data for minigenome activity and and mutation counts for viral competition are provided in [Figure 4---source datas 1](#fig4sdata1){ref-type="supplementary-material"} and [2](#fig4sdata2){ref-type="supplementary-material"}.\
10.7554/eLife.45079.014Figure 4---source data 1.Flow cytometry data for minigenome assays.\
10.7554/eLife.45079.015Figure 4---source data 2.Mutant frequency data for competition assay.](elife-45079-fig4){#fig4}

In contrast, all but one of the putative avian-adaptive mutations decreased transcriptional activity in human cells compared to wild type, as expected ([Figure 4A,B](#fig4){ref-type="fig"}). The one mutation that did not decrease transcriptional activity, I382D, had comparable activity to wild type. Finally, mutations that are putatively adaptive in both human and avian cells had modestly improved or comparable transcriptional activity in human cells compared to wild type.

We also tested the effect of some of the mutations on viral growth to capture any effects of mutations beyond transcriptional activity. We selected some mutations that increased transcriptional activity, and others that had no effect of transcriptional activity. Our rationale in these choices was to determine if mutations that were identified in our screen but did not increase transcriptional activity still resulted in improved viral growth in human over avian cells. For each competition, we infected human (A549) and avian (CCL-141) cells with mutant and wild-type viruses mixed at a 1:1 ratio of transcriptionally active particles as determined by flow cytometry for HA expression in infected cells. We then measured the frequencies of mutant to wild-type virus by deep sequencing. To measure kinetics of viral genome replication from a single round of infection, we infected cells at MOI of 0.1, collected samples at 10 hr post infection, and sequenced vRNA from cellular extract. To measure multi-cycle replication kinetics, we infected cells at MOI of 0.01, collected samples at 48 hr post infection, and sequenced vRNA from the supernatant. At the end of the infection, we calculated the ratio of mutant to wild-type virus in human cells divided by the same ratio in avian cells. Because this quantity is a ratio of ratios, it corrects for any possible deviations from a 1:1 ratio of infectious particles in the initial inoculum. Therefore, ratios greater than one indicates that the mutation confers a relative benefit for viral growth in avian versus human cells.

Almost all putative human-adaptive mutations identified in the deep mutational scanning improved growth in human over avian cells, as reflected by an increase in the ratio of mutant to wild type in human cells versus avian cells over the time course of the competition ([Figure 4C](#fig4){ref-type="fig"}, [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}). Of the putative human-adaptive mutations that did not improve polymerase activity, one mutation, R355G, improved growth in human over avian cells at both 10 and 48 hr post-infection. An additional mutation, R355K, slightly improved growth in human cells by 48 hr post-infection. These two mutations may therefore confer a human-specific growth benefit due to some mechanism other than polymerase activity. As expected, both putative avian-adaptive mutations resulted in poorer growth in human versus avian cells. Finally, the N82K mutation that is putatively adaptive in both human and avian cells resulted in comparable growth in both human and avian cells, as expected.

Thus, our deep mutational scanning identified numerous previously undescribed PB2 mutations that improve polymerase activity or viral growth in human cells. In addition, it also identified an intriguing small set of mutations that enhance viral growth but not polymerase activity in human cells.

Human-adaptive mutations cluster in regions of PB2 that are potentially important for host adaptation {#s2-5}
-----------------------------------------------------------------------------------------------------

The additional human-adaptive mutations we identified may improve PB2's ability to interact with important human cell factors. To identify potential interfaces for such interactions, we mapped the sites of top human-adaptive mutations identified in the deep mutational scanning onto the structure of PB2. Many of the sites cluster in regions of PB2 that may play a role in host adaptation ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

![Locations of top human-adaptive mutations on the structure of the influenza polymerase.\
Overall structure of the influenza polymerase complex comprising PB2, PB1 and PA in (**A, B**) the transcription pre-initiation form (PDB: 4WSB) and (**C, D**) the apo form (PDB: 5D98). PB2 domains defined as in [@bib66]. (**B, D**) Sites of top human-adaptive mutations identified by deep mutational scanning are shown in red on the PB2 subunit of the structure. Sites of previously experimentally verified human-adaptive mutations are in blue (25 sites as listed in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Sites identified by deep mutational scanning and which were also previously known are in purple. A subset of sites are labeled and/or circled for referencing in the main text, to indicate surfaces that might mediate host-interactions. Similar results are obtained if we instead analyze the structures in terms of a continuous variable representing the extent of human-specific adaptation at each site ([Figure 5---figure supplement 1B, C](#fig5s1){ref-type="fig"}). (**E**) Structure of PB2 C-terminal fragment co-crystalized with importin-α7 (PDB: 4UAD). Sites on PB2 interacting with major and minor NLS binding surfaces of importin-α7 are in green and cyan respectively. Importin-α7 is depicted in ribbon form in tan. We used the deep mutational scanning to define a continuous variable indicating the extent of host-specific adaptation at each site of PB2. Specifically, for each site, we computed the positive site differential selection by summing all positive mutation differential selection values at that site (i.e., the total height of the letter stack in the positive direction in logoplots such as in [Figure 3D](#fig3){ref-type="fig"}). We mapped this differential selection onto the PB2 C-terminal fragment in red; PB2 sites with high differential selection are numbered. Regions of importin-α7 that differ from importin-α3 are colored in orange, those near PB2 sites with high differential selection are shown as spheres. For all structures, the avian influenza (S009) PB2 amino acid sequence was mapped onto the PB2 chain by one-2-one threading using Phyre2 ([@bib44]) (Confidence in models for 4WSB, 5D98, and 4UAD are 100%, 100%, and 99% respectively). Sites are numbered according to the S009 PB2 sequence. [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} shows relative solvent accessibility of human-adaptive mutations, as well as positive site differential selection mapped onto structures of influenza polymerase.](elife-45079-fig5){#fig5}

Most adaptive mutations are surface exposed in at least one of the two conformations of the polymerase we examined ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}, relative solvent accessibility \>0.2). In the transcription pre-initiation form of the polymerase (PDB: 4WSB) ([@bib68]) ([Figure 5A,B](#fig5){ref-type="fig"}), the experimentally identified sites 532 and 292 are located on the surface near sites of known human-adaptive sites 286, 534, and 535 ([@bib12]; [@bib54]) ([Figure 5B](#fig5){ref-type="fig"}: i). Experimentally identified sites 69 and 82 are located on the surface close to sites 64 and 81 ([Figure 5B](#fig5){ref-type="fig"}: ii), which are located near the template exit channel and were recently shown to modulate generation of mini viral RNAs that act as innate-immune agonists ([@bib83]). Experimentally identified site 698 is located near known sites 701 and 702 ([@bib27]) ([Figure 5B](#fig5){ref-type="fig"}: iii, [Figure 5D](#fig5){ref-type="fig"}: i). Experimentally identified mutations are also located in regions not yet identified to be important for host-adaptation: we find a cluster of experimentally identified sites on the surface of the PB2-N terminal domain (169, 176, 183, 190, [Figure 5B](#fig5){ref-type="fig"}: iv), partially occluded by the flexible PA endonuclease domain in the transcription pre-initiation structure. Experimentally identified sites 163 and 182 are not surface exposed, but are buried right underneath the cluster of four sites.

Almost all sites that are not highly surface exposed in the transcription pre-initiation conformation of the polymerase become exposed upon conformational rearrangement of the polymerase from the transcription pre-initiation form to the apo form (PDB: 5D98) ([@bib37]). The experimentally identified sites 521 and 522 which face the product exit channel, site 355 which faces the core of the polymerase, and site 669 which faces PB1 in the transcription pre-initiation structure ([Figure 5B](#fig5){ref-type="fig"}: v -- vii), are more fully surface-exposed in the apo structure ([Figure 5C,D](#fig5){ref-type="fig"}: ii -- iv). However, some sites remain inaccessible: site 156 faces the internal core of the polymerase in both transcription pre-initiation and apo forms ([Figure 5B](#fig5){ref-type="fig"}: viii, [Figure 5D](#fig5){ref-type="fig"}: v). Therefore, with only a few exceptions, the human-adaptive mutations cluster in patches on the surface of PB2. Taking a comprehensive approach has therefore allowed us to map surfaces of PB2 that might mediate host-interactions.

Next, we asked if host-adaptation mutations occur at known interaction interfaces with host proteins. One known interacting host protein is importin-α, which mediates nuclear import of PB2 and has been proposed to have a role in viral transcription and replication ([@bib70]; [@bib80]). PB2 of avian viruses uses importin-α3 in human cells, whereas PB2 of mammalian-adapted viruses uses importin-α7 ([@bib29]; [@bib28]). We mapped total positive differential selection on each site of PB2 (see legend for [Figure 5E](#fig5){ref-type="fig"}), and asked how this selection on PB2 relates to its interaction with importin-α. Sites on PB2 that interact with the major and minor NLS-binding surfaces of importin-α ([@bib67]; [@bib80]) generally have low differential selection, indicating that host-adaptation mutations do not occur at these sites ([Figure 5E](#fig5){ref-type="fig"}; PDB: 4UAD) ([@bib67]). This is expected, since all importin-α isoforms share an invariant NLS-binding surface. However, adjacent PB2 sites have higher differential selection ([Figure 5E](#fig5){ref-type="fig"}: i-iii). Some of these PB2 sites are in close proximity to regions of importin-α that differ between the α−7 and α−3 isoforms ([Figure 5D](#fig5){ref-type="fig"}: i, iii), suggesting that adaptation at these PB2 sites affects importin-α usage.

PB2 also interacts with the C-terminal domain of RNA polymerase II, and this interaction is proposed to stabilize the polymerase in the transcription-competent conformation (PDB: 6F5O) ([@bib74]). Similar to what we observe with importin-α, PB2 sites thought to directly interact with RNA polymerase II tend to have low differential selection, whereas adjacent PB2 sites have higher differential selection ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). Thus, it appears that host adaptation may involve mutations at sites adjacent to the core residues that directly interact with host proteins.

Experimentally defined human-adaptive mutations are enriched in avian-to-human transmission of H7N9 influenza {#s2-6}
-------------------------------------------------------------------------------------------------------------

A challenge in the surveillance of non-human influenza and assessment of pandemic risk is determining which of the many mutations that occur during viral evolution are human-adaptive ([@bib49]; [@bib72]). We investigated whether our experimental measurements can identify host-adaptation mutations that occur during the actual transmission of avian influenza to humans.

Avian H7N9 influenza viruses have recently caused a large number of sporadic human infections ([@bib76]). We examined mutations occurring during the evolution of H7N9 viruses that have jumped from avian to human hosts to determine whether they were enriched for changes predicted by our deep mutational scanning to be human adaptive. First, we constructed a phylogeny of H7N9 PB2 sequences, inferred ancestral sequences for all internal nodes, and assigned mutations to specific branches of the phylogenetic tree ([Figure 6A](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}--[5](#fig6s5){ref-type="fig"}). We then classified each mutation on the phylogenetic tree as 'avian' or 'human' based on whether it occurred on a branch connecting two avian isolates, or on a branch leading to a human isolate respectively ([Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). As human infections by H7N9 are evolutionary dead-ends, mutations occurring during human infections should appear immediately proximal to human isolates in the phylogeny, while mutations occurring during bird infections will be ancestral.

![Experimentally identified human-adaptive mutations are enriched in avian-human transmission of H7N9 influenza.\
(**A**) Phylogeny of H7N9 influenza PB2 sequences. Branches in human and avian hosts are colored black and gray respectively. Orange or red dots indicate where a mutation was inferred to have occurred. Branch lengths are scaled by annotated and inferred dates of origin of each sequence. (**B**) Distribution of experimentally measured differential selection values for all mutations occurring during H7N9 evolution in human and avian hosts. A positive differential selection value means that our experiments measured the mutation to be beneficial in human versus avian cells. A subset of top differentially selected mutations that occur frequently are labeled and plotted in orange. Enlarged phylogenetic trees are in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}--[5](#fig6s5){ref-type="fig"}. Counts of mutations identified in phylogenetic analysis are in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}. Mutations plotted in each bin of the histogram are in [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}.\
10.7554/eLife.45079.024Figure 6---source data 1.H7N9 human and avian mutation counts.\
10.7554/eLife.45079.025Figure 6---source data 2.H7N9 human and avian mutation differential selection values and counts in each histogram bin.](elife-45079-fig6){#fig6}

We next asked whether mutations occurring in human hosts had higher differential selection values in our deep mutational scanning than mutations in avian hosts. Indeed, human mutations more often had high differential selection (a value \>0.5) than avian mutations (Fisher's exact test, p=2.69e-7) ([Figure 6B](#fig6){ref-type="fig"}). The H7N9 human mutations with differential selection \>0.5 include the well-studied human-adaptive mutations 627K and 701N. Indeed, these two mutations make up the majority of H7N9 human mutations with high differential selection. But we also identified a number of other mutations with high differential selection that occurred at least four independent times in jumps of H7N9 influenza into humans: 627V, 534F, 355K, and 521I ([Figure 6A](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}--5, 6B, 3D), only one of which has been previously characterized (E627V, [@bib78]). A second mutation at site 355 (355G) with high differential selection also occurs during jumps of H7N9 influenza into humans. Thus, our deep mutational scanning identifies both previously characterized and novel mutations that occur in natural avian-to-human transmission of influenza.

Most human-adaptive mutations are not accessible by single nucleotide substitutions {#s2-7}
-----------------------------------------------------------------------------------

Our deep mutational scanning identifies many human-adaptive mutations. Why do we not observe all of them in nature? One possible explanation is that some of these mutations are inaccessible by single nucleotide substitution from existing sequences, and are therefore less likely to arise during natural evolution ([@bib26]).

We examined if accessibility by single nucleotide substitution imposes constraint on which human-adaptive mutations arise in nature. To do so, we calculated the mean nucleotide substitutions required to access known human-adaptive mutations from all avian influenza PB2 sequences collected in the past three years. This mean number of nucleotide substitutions can range from less than one (if the mutation is already present in some avian PB2 sequences) to three (if the mutation requires three nucleotide changes from all avian PB2 sequences). The majority of previously characterized human-adaptive mutations are accessible by single nucleotide substitutions from avian PB2 sequences ([Figure 7](#fig7){ref-type="fig"}), suggesting that these mutations have already been characterized because they readily occur in the context of current avian influenza viruses. In contrast, most of the top human-adaptive mutations identified in our deep mutational scanning require multiple nucleotide substitutions from current avian PB2 sequences ([Figure 7](#fig7){ref-type="fig"}). Therefore, many of the novel human-adaptive mutations uncovered by our experiment have probably not been previously identified because they are evolutionarily inaccessible from current avian influenza sequences.

![Evolutionary accessibility of mutations from current avian influenza PB2 sequences.\
Distribution of mean nucleotide substitutions required to access all amino-acid mutations, previously characterized human-adaptive mutations, and top human-adaptive mutations identified in our deep mutational scanning. Mean nucleotide substitution is calculated by averaging over all avian influenza PB2 sequences collected from 2015 to 2018. Most previously characterized human-adaptive mutations are accessible by single nucleotide substitution, whereas many of the new adaptive mutations that we identified require multiple nucleotide substitutions. Mean nucleotide substitutions for each mutation are in [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.45079.027Figure 7---source data 1.Mean nucleotide substitutions from avian sequences of all mutations.](elife-45079-fig7){#fig7}

The importance of evolutionary accessibility is especially obvious if we examine the adaptive mutations that actually occur in natural influenza virus evolution. Of the five top human adaptive mutations accessible by single nucleotide substitution ([Figure 7](#fig7){ref-type="fig"}), three have occurred repeatedly during recent transmissions of H7N9 influenza to humans (355G, 521I, 701N; see [Figure 6A](#fig6){ref-type="fig"}). Thus, it may be possible to combine deep mutational scanning measurements of phenotypes with analyses of evolutionary accessibility to anticipate which mutations are most likely to arise in the context of any given starting sequence ([@bib26]).

Discussion {#s3}
==========

We have measured how all single amino-acid mutations to an avian influenza PB2 affect viral growth in both human and avian cells. Our results separate the constraints on PB2 into those that are maintained across cells from diverse species versus those that are specific to human or avian cells. The vast majority of sites are under extremely similar constraint in human and avian cells, including at residues already known to be critical for PB2 function. Layered upon this conserved constraint are mutations with host-specific effects. Our approach therefore represents a powerful strategy for mapping viral determinants of cross-species transmission.

The viral determinants of influenza host specificity in the PB2 protein have been intensely studied for decades. Earlier studies addressing this question focused on mutations that have fixed during viral adaptation in nature or in the lab ([@bib11]; [@bib12]; [@bib14]; [@bib24]; [@bib27]; [@bib41]; [@bib40]; [@bib45]; [@bib54]; [@bib57]; [@bib58]; [@bib59]; [@bib61]; [@bib79]; [@bib92]; [@bib93]). Recent studies have sampled more mutations by random mutagenesis at key sites such as positions 627, 701, and 702 of PB2 ([@bib15]; [@bib16]), or error prone PCR across the genome ([@bib78]). We can now place these previously characterized mutations in the context of a complete map, thus revealing how selection at molecular interfaces and evolutionary accessibility shapes influenza's adaptation to humans.

Examination of our maps of differential selection at known molecular interfaces, such as with importin-α ([@bib67]; [@bib80]) and RNA polymerase II ([@bib74]) suggest an interesting hypothesis: host-adaptive mutations are located adjacent to but not at core residues that directly interact at host proteins, suggesting that host adaptation may involve mutations at sites at the periphery of core interactions. Of course, it remains unclear precisely how any of these new human-adaptive mutations act, though initial validations show that most improve polymerase activity in human cells. However, an intriguing set of mutations such as at site 355 improve viral growth but not polymerase activity in human cells. We speculate that the effects of these mutations on viral growth are mediated by other effects of PB2, such as in modulating the innate-immune response ([@bib33]; [@bib83]).

Even though we have focused our analyses mostly on host-adaptive mutations, our measurements are also useful to studies of PB2 function independent of host adaptation. Our complete maps of amino acid preferences in each cell type provide context for the handful of residues well-known to be critical for PB2 functions. For example, although our data recapitulate most of the known functional constraints on sites previously defined to be critical for mRNA cap-binding ([@bib35]), they also reveal that some of these sites can tolerate alternate residues. Thus, our complete survey of the mutational constraints at each site complements other functional and structural knowledge.

We also show that our comprehensive experimental measurements can identify human-adaptive mutations that occur during avian-to-human transmission of H7N9 influenza. These measurements therefore help address a fundamental challenge in assessing the risk of potential pandemic influenza virus strains: determining which of the many mutations observed during viral surveillance affect whether a virus will be successful in human hosts ([@bib49]; [@bib72]). Our high-throughput approach therefore enables phenotypic measurements to keep pace with the challenge of interpreting the many viral mutations that are observed during genotypic surveillance of virus evolution ([@bib34]).

However, although some amino-acid mutations we experimentally identified as human-adaptive occur frequently in nature, others have never been observed. In addition, the strengths of differential selection measured in our experiments do not necessarily correspond to observed frequencies of mutations in nature. These apparent inconsistencies highlight the important role of evolutionary accessibility in shaping influenza's host adaptation. First, most human-adaptive mutations observed in natural influenza evolution are accessible by single nucleotide substitution from current avian genotypes, demonstrating how the architecture of the genetic code impacts viral adaptation ([@bib26]). Second, even among single-nucleotide substitutions, transition mutations are about ten-fold more frequent than transversions during influenza replication ([@bib5]). This might explain why E627K (which requires a G→A transition) is much more frequently observed than E627V (which requires a A→T transversion), despite the latter being more strongly selected in human cells in our experiments. Of course, many additional factors not captured by our experiments can impact which adaptive mutations fix in nature. Integrating our complete maps of the effects of amino-acid mutations with other data that sheds light on evolutionary opportunity, such as nucleotide accessibility, mutation rates, transmission bottlenecks, and environmental and epidemiological factors ([@bib30]; [@bib31]; [@bib60]; [@bib63]; [@bib65]; [@bib87]) will help us understand how viruses cross species barriers in nature.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\           Designation             Source or reference                          Identifiers                                                                                              Additional\
  (species) or resource                                                                                                                                                                                 information
  ----------------------- ----------------------- -------------------------------------------- -------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Cell line\              A549                    ATCC                                         CCL-185;\                                                                                                
  (Homo sapiens)                                                                               RRID:[CVCL_0023](https://scicrunch.org/resolver/CVCL_0023)                                               

  Cell line\              HEK293T                 ATCC                                         CRL-3216;\                                                                                               
  (Homo sapiens)                                                                               RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)                                               

  Cell line\              MDCK-SIAT1              Sigma-Aldrich                                5071502;\                                                                                                
  (Canis familiaris)                                                                           RRID:[CVCL_Z936](https://scicrunch.org/resolver/CVCL_Z936)                                               

  Cell line\              CCL-141                 ATCC                                         CCL-141;\                                                                                                
  (Anas platyrhynchus\                                                                         RRID:[CVCL_T](https://scicrunch.org/resolver/CVCL_T281)[281](https://scicrunch.org/resolver/CVCL_T281)   
  domesticus)                                                                                                                                                                                           

  Cell line\              MDCK-SIAT1-tet-\        this paper                                                                                                                                            MDCK-SIAT1 cells\
  (Canis familiaris)      S009-PB2-E627K                                                                                                                                                                expressing S009 PB2-E627K\
                                                                                                                                                                                                        under control of a\
                                                                                                                                                                                                        doxycycline-inducible\
                                                                                                                                                                                                        promoter

  Recombinant\            pHW_noCMV_S009_PB2;\    this paper                                                                                                                                            Plasmids for generating\
  DNA reagent             pHW_noCMVnoTerm_BsmBI                                                                                                                                                         mutant plasmid\
                                                                                                                                                                                                        library; see\
                                                                                                                                                                                                        [Supplementary file 1](#supp1){ref-type="supplementary-material"}

  Recombinant\            pHW_S009_PB2;\          this paper                                                                                                                                            Plasmids for generating\
  DNA reagent             pHW_S009_PB1;\                                                                                                                                                                helper virus; see\
                          pHW_S009_PA;\                                                                                                                                                                 [Supplementary file 1](#supp1){ref-type="supplementary-material"}
                          pHW_S009_NP                                                                                                                                                                   

  Recombinant\            HDM_S009_PB2;\          this paper                                                                                                                                            Plasmids for protein\
  DNA reagent             HDM_S009_PB1;\                                                                                                                                                                expression of S009\
                          HDM_S009_PA;\                                                                                                                                                                 polymerase complex;\
                          HDM_S009_NP                                                                                                                                                                   see [Supplementary file 1](#supp1){ref-type="supplementary-material"}

  Recombinant\            pHH_PB2_S009_flank\     this paper                                                                                                                                            Plasmids for generating\
  DNA reagent             \_99_eGFP_100                                                                                                                                                                 helper virus; see\
                                                                                                                                                                                                        [Supplementary file 1](#supp1){ref-type="supplementary-material"}

  Recombinant\            pHW184_HA;\             [@bib39]                                                                                                                                              
  DNA reagent             pHW186_NA;\                                                                                                                                                                   
                          pHW187_M;\                                                                                                                                                                    
                          pHW188_NS                                                                                                                                                                     

  Recombinant\            pHH-PB1-flank-eGFP      [@bib4]                                                                                                                                               Reporter plasmid for\
  DNA reagent                                                                                                                                                                                           minigenome assay;\
                                                                                                                                                                                                        see [Supplementary file 1](#supp1){ref-type="supplementary-material"}

  Recombinant\            pcDNA3.1_mCherry        this paper                                                                                                                                            Transfection control\
  DNA reagent                                                                                                                                                                                           for minigenome\
                                                                                                                                                                                                        assay; see\
                                                                                                                                                                                                        [Supplementary file 1](#supp1){ref-type="supplementary-material"}

  Recombinant\            pSBtet_RP_S009\         this paper                                                                                                                                            Plasmid for generating\
  DNA reagent             \_PB2_E627K                                                                                                                                                                   PB2-expressing cell\
                                                                                                                                                                                                        line; see [Supplementary file 1](#supp1){ref-type="supplementary-material"}

  Sequence-based\         primers                 this paper                                                                                                                                            See [Supplementary file 2](#supp2){ref-type="supplementary-material"}
  reagent                                                                                                                                                                                               

  Commercial\             NEBuilder HiFi\         New England Biolabs                          E2621S                                                                                                   
  assay or kit            DNA Assembly\                                                                                                                                                                 
                          Master Mix                                                                                                                                                                    

  Commercial\             ElectroMAX DH10B\       Invitrogen                                   18290015                                                                                                 
  assay or kit            competent cells                                                                                                                                                               

  Commercial\             Rneasy Mini Kit         Qiagen                                       74104                                                                                                    
  assay or kit                                                                                                                                                                                          

  Commercial\             Accuscript Reverse\     Agilent                                      200820                                                                                                   
  assay or kit            Transcriptase                                                                                                                                                                 

  Commercial\             KOD Hot Start Master\   EMD Millipore                                71842                                                                                                    
  assay or kit            Mix                                                                                                                                                                           

  Commercial\             QIAamp Viral RNA\       Qiagen                                       52904                                                                                                    
  assay or kit            Mini Kit                                                                                                                                                                      

  Commercial\             SuperScript III         ThermoFisher Scientific                      18080051                                                                                                 
  assay or kit                                                                                                                                                                                          

  Chemical\               BioT                    Bioland Scientific                           B01-01                                                                                                   
  compound, drug                                                                                                                                                                                        

  Chemical\               Lipofectamine 3000      ThermoFisher\                                L3000015                                                                                                 
  compound, drug                                  Scientific                                                                                                                                            

  Antibody                H17-L19                 [@bib32]                                                                                                                                              

  Software,\              dms_tools2              <https://jbloomlab.github.io/dms_tools2>,\                                                                                                            
  algorithm                                       version 2.3.0                                                                                                                                         

  Software,\              Jupyter notebooks\      this paper                                                                                                                                            See\
  algorithm               that perform all\                                                                                                                                                             [Supplementary file 3](#supp3){ref-type="supplementary-material"};\
                          steps of analyses                                                                                                                                                             <https://github.com/jbloomlab/PB2-DMS>
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell lines and media {#s4-1}
--------------------

HEK293T, MDCK-SIAT1, and A549 (ATCC CCL-185) cells were maintained in D10 media (DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml of streptomycin). CCL-141 cells (ATCC CCL-141) were maintained in E10 media (identical to D10 except that EMEM is used in place of DMEM). Cells were grown in WSN growth media (WGM: Opti-MEM supplemented with 0.5% FBS, 0.3% BSA, 100 µg/ml CaCl~2~, 100 U/ml penicillin, and 100 μg/ml of streptomycin) for viral infections.

For an avian cell line, we chose to use a duck rather than a chicken cell line because ducks are natural hosts of influenza that (unlike chickens) possess RIG-I, a key innate-immune sensor of influenza ([@bib3]).

For expansion of helper virus, we generated MDCK-SIAT1 cells expressing S009 PB2-E627K under control of a doxycycline-inducible promoter (MDCK-SIAT1-tet-S009-PB2-E627K) using a Sleeping Beauty transposon system ([@bib46]). Briefly, MDCK-SIAT1 cells were transfected with pSBtet_RP_S009_PB2_E627K and pSB100X transposase vector using Lipofectamine 3000 (ThermoFisher Scientific, L3000015), and then subject to selection with 1 µg/ml puromycin. At three days post-transfection, we sorted for individual transfected cells expressing mCherry. All subsequent experiments were performed with a clonal expansion of a single transfected cell.

A549 cells were authenticated using the ATCC STR profiling service. CCL-141 cells were obtained from ATCC and used without extensive passaging. All cell lines tested negative for mycoplasma at the time they were expanded for either generating helper virus or passaging mutant plasmid libraries.

Plasmids {#s4-2}
--------

Sequences for plasmids generated in this study are provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Avian influenza polymerase plasmids: Original plasmids for PB2, PB1, PA, and NP genes from avian influenza strain A/Green-winged Teal/Ohio/175/1986 (S009) were gifts of Jeffrey Taubenberger ([@bib42]). For generating the mutant plasmid library, we cloned the S009 PB2 coding sequence into a pHW2000 vector ([@bib39]) from which we removed the CMV promoter (final plasmid pHW_noCMV_S009_PB2). The mutant library insert was cloned into the recipient vector pHW_noCMVnoTerm_BsmBI, which lacks the Pol I terminator (terminator sequence is part of the insert). The reason that we generated a pHW plasmid without a CMV promoter is that we were unable to maintain a stable bacterial clone of the S009 PB2 coding sequence on the pHH21 plasmid backbone -- we observed frequent deletions in the coding sequence during plasmid propagation, suggesting that the insert on the pHH21 plasmid backbone is toxic to the bacterial host. For generating helper virus and virus for viral competitions, we cloned the S009 PB2, PB1, PA, and NP coding sequences into pHW2000 (pHW_S009_PB2, pHW_S009_PB1, pHW_S009_PA, pHW_S009_NP). In all cases we used non-coding viral-RNA termini from the respective A/WSN/1933(H1N1) gene segment. For protein expression and the minigenome assay, we cloned the PB2, PB1, PA, and NP coding sequences from S009 into a protein-expression plasmid with a CMV promoter (HDM_S009_PB2, HDM_S009_PB1, HDM_S009_PA, HDM_S009_NP). All mutants of PB2 were made by site-directed mutagenesis on the appropriate plasmid backbone.

Helper virus plasmids: To generate a PB2 vRNA lacking a functional PB2 protein, we cloned GFP flanked by PB2 sequence into the pHH21 vector ([@bib62]) (pHH_PB2_S009_flank_99_eGFP_100). The flanking non-coding viral-RNA termini are from WSN PB2, and the coding sequences are from S009 PB2. The length of flanking sequences, 99 and 100 bases on the 5' and 3' end of the PB2 coding sequence respectively, are based on prior experiments analyzing how much terminal sequence is needed for effective genome packaging ([@bib48]). We mutated out start codons 5' to the GFP start site in the mRNA sense. Our helper virus rescue also required the reverse genetics plasmids encoding HA, NA, M, and NS from WSN (pHW184_HA, pHW186_NA, pHW187_M, pHW188_NS) ([@bib39]). To generate a cell line with doxycycline-inducible expression of S009 PB2 for expansion of PB2-deficient helper virus, we cloned the S009 PB2-E627K coding sequence into the pSBtet vector (pSBtet_RP_S009_PB2_E627K) ([@bib46]).

Minigenome assay: In addition to protein expression plasmids described above, we used a pHH-PB1-flank-eGFP reporter ([@bib4]), and pcDNA3.1-mCherry as a transfection control.

Primers {#s4-3}
-------

All primer sequences used in this study are provided in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. Note that this Excel file has several worksheets giving primers for different aspects of the experiments.

PB2 codon mutant plasmid libraries {#s4-4}
----------------------------------

We generated all possible codon mutations of the entire PB2 coding sequence using the PCR-based strategy described in [@bib5] with the modifications described in [@bib17]. Briefly, we designed mutagenic primers tiling across the entire coding region (<https://github.com/jbloomlab/CodonTilingPrimers>; [@bib9]; copy archived at <https://github.com/elifesciences-publications/CodonTilingPrimers>). We performed 10 cycles of fragment PCR using the mutagenic primers and end primers flanking the vRNA, followed by 20 cycles of joining PCR using only end primers ([Supplementary file 2](#supp2){ref-type="supplementary-material"}: Mutagenesis worksheet). We generated three independent libraries starting from mutagenesis of independent bacterial clones. The PB2 variants were cloned into the BsmBI-digested vector pHW_noCMVnoTerm_BsmBI using NEBuilder HiFi DNA Assembly Master Mix (NEB, E2621S), and electroporated into ElectroMAX DH10B competent cells (Invitrogen, 18290015). We obtained 18--22 million transformants for each replicate library, from which we extracted plasmid by maxiprep. We randomly selected 48 clones for Sanger sequencing to evaluate the library mutation rate (<https://github.com/jbloomlab/SangerMutantLibraryAnalysis>; [@bib8]; copy archived at <https://github.com/elifesciences-publications/SangerMutantLibraryAnalysis>).([Figure 1---figure supplement 2A--F](#fig1s2){ref-type="fig"}).

Generation and passaging of mutant virus libraries {#s4-5}
--------------------------------------------------

We generated mutant virus libraries using the helper-virus approach in [@bib21], with modifications. We rescued reassortant virus using polymerase and nucleoprotein genes (PB2, PB1, PA, NP) from S009, and remaining genes (HA, NA, M, NS) from A/WSN/1933(H1N1) (WSN).

Helper virus: We plated a co-culture of 4 × 10^5^ HEK293T and 0.5 × 10^5^ MDCK-SIAT1-tet-S009-PB2-E627K in D10 media per well of a 6-well plate. At 18 hr after seeding cells, we added 1 µg/ml doxycycline to induce PB2 expression. One hour after adding doxycycline, we transfected each well with 250 ng each of pHH_PB2_S009_flank_99_eGFP_100, HDM_S009_PB2-E627K, pHW_S009_PB1, pHW_S009_PA, pHW_S009_NP, pHW184_HA, pHW186_NA, pHW187_M, and pHW188_NS using BioT (Bioland Scientific, B01-01). At four hours post-transfection, we replaced D10 media with WGM supplemented with 1 µg/ml doxycycline. We collected viral supernatant 52 hr post-transfection. To expand the helper virus, we seeded MDCK-SIAT1-tet-S009-PB2-E627K cells in D10 media 4 hr prior to infection at 4 × 10^6^ cells per 15 cm dish. We then infected each dish with 40 µl of fresh viral supernatant, using WGM supplemented with 1 µg/ml doxycycline to induce PB2 expression. At 48 hr post-infection, we collected viral supernatant containing expanded helper virus and clarified the supernatant by centrifugation at 400x g for 4 min. We measured the infectious particle (IP)/µl titer of the helper virus by infecting HEK293T cells with a known volume of viral supernatant, and quantifying the number of GFP+ cells by flow cytometry 18 hr post-infection.

Mutant virus library rescue: For each mutant plasmid library, we seeded 36 wells of a 6-well dish with 1 × 10^6^ HEK293T cells, and transfected each well 17 hr later with 375 ng each of HDM_S009_PB2-E627K, HDM_S009_PB1, HDM_S009_PA, HDM_S009_NP, and 500 ng of PB2 mutant plasmid library using BioT. For the wild-type control, we seeded six wells and used pHW_noCMV_S009_PB2 in place of the mutant plasmid library. At 6 hr post-transfection, we infected cells with helper virus at MOI of 1 IP/cell in WGM. At 2 hr post-infection, we replaced the inoculum with fresh WGM. At 20 hr post-infection, we harvested viral supernatants and clarified the supernatant by centrifugation at 400x g for 4 min. Supernatants were titered by TCID~50~ on MDCK-SIAT1 cells. The titers for the three library replicates and wild-type control were 262, 68, 100, and 1467 TCID~50~/µl respectively.

Passaging of mutant virus libraries: We aimed to passage 1 × 10^6^ TCID~50~ of each mutant virus library in A549 and CCL-141 cells at MOI of 0.01 TCID~50~/cell as determined in MDCK-SIAT1 cells. Therefore, we aimed to have 1 × 10^8^ total cells each at the time of infection. The day prior to each infection, we seeded between 8 × 10^7^ to 1 × 10^8^ A549 cells in D10 in 4 × 5 layered cell culture flasks (Corning, 353144), and 8 × 10^7^ to 1 × 10^8^ CCL-141 cells in E10 in 8 × 5 layered cell culture flasks. To estimate the total number of each cell type at the time of each infection, we plated an equivalent density of cells in a T225 flask. Just prior to infection, we counted the number of cells in the T225 flask, and extrapolated the total number of cells to be infected. We calculated, for an MOI of 0.01, the number of TCID~50~s to be passaged for each of the three library replicates and wild-type control in A549 cells to be 9.39 × 10^5^, 1.02 × 10^6^, 1.20 × 10^6^, and 9.30 × 10^5^ respectively, and in CCL-141 cells to be 8.46 × 10^5^, 8.92 × 10^5^, 9.54 × 10^5^, and 8.58 × 10^5^ respectively. We infected cells by removing D10 or E10 media, rinsing each flask with PBS, and then adding the calculated amount of virus diluted in WGM. At 3 hr post-infection, we replaced the inoculum with fresh WGM. The low MOI passage is expected to purge any non-replicative virus, including those containing the GFP segment. We confirmed this by our observation that there is limited spread of GFP expression over the course of infection. We harvested viral supernatant 48 hr post-infection, and clarified the supernatant by centrifugation at 400x g for 4 min.

Barcoded subamplicon sequencing {#s4-6}
-------------------------------

We ultracentrifuged clarified viral supernatant at 27,000 rpm in a Beckman Coulter SW28 rotor, for 2 hr at 4°C. We resuspended the virus the residual media, then extracted RNA from 280 µl of concentrated virus using the Qiagen RNeasy Mini Kit (Qiagen, 74104). We titered the concentrated viral supernatant by TCID~50~ on MDCK-SIAT1 cells to estimate the total TCID~50~ from which we extracted RNA (ranged from 2.80 × 10^5^ to 8.8 × 10^6^ TCID~50~); we expect the TCID~50~ titer to be a lower-bound and underestimate of the total viral variants present in the supernatant, since it measures only infectious virus, whereas we would extract RNA from both infectious and non-infectious virions.

We used a barcoded-subamplicon deep sequencing strategy that reduces the sequencing error rate ([@bib21]), <https://jbloomlab.github.io/dms_tools2/bcsubamp.html>). Briefly, we reverse transcribed the full PB2 vRNA with Accuscript Reverse Transcriptase (Agilent, 200820) (primer S009-PB2-full-1F, [Supplementary file 2](#supp2){ref-type="supplementary-material"}: Barcoded subamplicon sequencing worksheet), and then PCR amplified the full PB2 vRNA (primers S009-PB2-full-1F and S009-PB2-full-8R, [Supplementary file 2](#supp2){ref-type="supplementary-material"}) using KOD Host Start Master Mix (EMD Millipore, 71842), making sure to have amplified from an estimated 1 × 10^7^ cDNA molecules. During this amplification, we observed that the band corresponding to full-length PB2 was generally more intense than the smaller bands likely corresponding to the PB2-GFP gene segment, as well as PB2 deletions, suggesting that full-length PB2 was the most prevalent ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). We then PCR amplified the PB2 gene in eight subamplicons using primers containing a random barcode to uniquely identify each template cDNA molecule ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Approximately 7.5 × 10^5^ uniquely barcoded molecules from each subamplicon library were then amplified by primers that add Illumina sequencing adaptors ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Finally, these libraries were deep sequenced on an Illumina HiSeq 2500 using 2 × 250 bp paired-end reads to a target 3.3x coverage per barcode.

Analysis of deep mutational scanning data {#s4-7}
-----------------------------------------

Deep mutational scanning sequence data was analyzed using dms_tools2 (<https://jbloomlab.github.io/dms_tools2>, version 2.3.0). The GitHub repository <https://github.com/jbloomlab/PB2-DMS> ([@bib75]; copy archived at <https://github.com/elifesciences-publications/PB2-DMS>) contains Jupyter notebooks that perform all steps of the analyses and provide detailed step-by-step explanations and plots. The README file explains the organization of the notebooks and other files. HTML renderings of the notebooks are provided in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. Processed results on preferences, differential selection, and mutation effect are provided in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.

Rescaling of preferences: We rescaled our preferences to match the stringency of selection in nature. To do so, we first asked how well the preferences measured by the deep mutational scanning in either human or avian cells describes evolution of PB2 in both human and avian hosts. We used the preferences to generate an experimentally informed codon substitution model (ExpCM) ([@bib7]; [@bib38]), and asked if the ExpCMs described PB2's natural evolution better than a standard phylogenetic substitution model. The ExpCMs using amino-acid preferences vastly outperformed standard phylogenetic substitution models, suggesting that our experiments do capture some of the natural evolutionary constraint on PB2 ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The ExpCM stringency parameter had a value of 2.5, indicating that natural selection favors the same amino acids as our experiments, but with greater stringency ([@bib38]). We thus rescaled our preferences to match the stringency of selection in nature using the ExpCM stringency parameter, and use these rescaled preferences for all subsequent analyses ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}).

Minigenome activity {#s4-8}
-------------------

Minigenome assays were performed in biological triplicate (starting from independent bacterial clones of each PB2 mutant) in both A549 and HEK293T cells. We seeded 2.5 × 10^4^ A549 or HEK293T cells per well of a 96-well plate. Cells were transfected the next day with 10 ng each of HDM_S009_PB2 (for the respective mutant), HDM_S009_PB1, HDM_S009_PA, HDM_S009_NP, 30 ng of pHH-PB1-flank-eGFP reporter, and 30 ng of pcDNA-mCherry as transfection control, using Lipofectamine 3000 (A549) or BioT (HEK293T). At 22 hr post-transfection, cells were trypsinized and analyzed by flow cytometry. We report minigenome activity as the percent of mCherry-positive cells that are GFP-positive.

Viral competition {#s4-9}
-----------------

Mutant virus: We generated mutant virus by reverse genetics using pHW_S009_PB2 (for the respective mutant), pHW_S009_PB1, pHW_S009_PA, pHW_S009_NP, pHW184_HA, pHW186_NA, pHW187_M, and pHW188_NS. We seeded 5 × 10^5^ HEK293T cells per well of a 6-well plate, and transfected cells the next day with 250 ng each of the 8 pHW plasmids using BioT. At 2 hr post-transfection, we replaced media with WGM. At 40 hr post-infection, we collected viral supernatant. Viruses were titered by measuring the number of transcriptionally active particles as determined by flow cytometry for HA expression in infected A549 and CCL-141 cells. Briefly, we infected A549 and CCL-141 cells with a known volume of viral supernatant, and quantified the number of HA+ cells 9 hr post-infection. Cells were stained for HA using the H17-L19 antibody ([@bib32]), which reacts with the WSN HA ([@bib20]).

Competitions: Viral competition assays were performed in biological duplicate (starting from independent bacterial clones of each PB2 mutant). For each competition, A549 and CCL-141 cells were infected with a mixture of wild-type and PB2-mutant virus at a 1:1 ratio of transcriptionally active particles as measured for that cell type. For samples collected at 10 hr post infection, we infected a minimum of 3.78 × 10^5^ cells at MOI of 0.1. For samples collected at 48 hr post infection, we infected a minimum of 7.62 × 10^5^ cells at MOI of 0.01. At 2 hr post-infection, we replaced either D10 or E10 media with fresh WGM. At 10 hr post-infection, cells infected at MOI of 0.1 were lysed in buffer RLT and cellular RNA was extracted using the Qiagen RNeasy Mini Kit. At 48 hr post-infection, we collected viral supernatant from cells infected at MOI of 0.01, and extracted RNA using the QIAamp Viral RNA Mini Kit (Qiagen, 52904).

Sequencing to determine mutant frequency: We reverse transcribed the full length PB2 vRNA from the extracted RNA with SuperScript III (ThermoFisher Scientific, 18080051) (primer S009-PB2-full-1F, [Supplementary file 2](#supp2){ref-type="supplementary-material"}: Viral competition). For each PB2 mutant, we PCR amplified from the cDNA the region of PB2 centered around that mutated codon site ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). This product was then subject to a second PCR using primers that add Illumina sequencing adaptors. Finally, these libraries were deep sequenced on an Illumina MiSeq using 50 bp single-end reads. Computational analyses to quantify mutant versus wild-type frequency are provided in [Supplementary file 3](#supp3){ref-type="supplementary-material"}, and at <https://github.com/jbloomlab/PB2-DMS.>

H7N9 phylogenetic analysis {#s4-10}
--------------------------

The phylogenetic tree was generated using Nextstrain's augur pipeline ([@bib36]), and ancestral state reconstruction and adjustment of branch lengths according to sequence isolation date were performed with TreeTime ([@bib73]). Ancestral state reconstruction was only performed for nucleotide states, and was not used to infer ancestral host states. Instead, we inferred host-state transitions associated with each branch of the tree in a way that leveraged the prior knowledge that most H7N9 viruses circulate in avian hosts, and that most human infections arise from direct avian-to-human transmissions ([@bib76]). Specifically, for each node in the tree, starting from the root, we gathered all tips descending from that node. If that clade included only human sequences, and its parent node also included only human sequences, then the current clade falls within a monophyletic human clade, and the branch leading to it was labeled human-to-human. If the current clade includes only human sequences but the parent node includes non-human sequences, then the branch leading to the clade was labeled avian-to-human. If the current clade includes both human and non-human sequences, then the branch leading to the clade was labeled avian-to-avian. Mutations were classified as human if they occurred on human-to-human and avian-to-human branches, and are classified as avian if they occurred on avian-to-avian branches. Note that since H7N9 human influenza typically results from avian-to-human transmissions, the branches we label as human-to-human in reality likely arise from avian-to-human transmissions, but which we cannot accurately reconstruct due to insufficient sampling of avian sequences. For this reason, human-to-human and avian-to-human branches were grouped together. Further details are provided in Jupyter notebook at <https://github.com/jbloomlab/PB2-DMS>, or in [Supplementary file 3](#supp3){ref-type="supplementary-material"}.

Accessibility of mutations {#s4-11}
--------------------------

We calculated the accessibility, or mean nucleotide substitutions required to access an amino-acid mutation, from avian influenza PB2 sequences collected from 2015 through 2018. The accessibility of codon *c* to amino-acid *a* by single-nucleotide mutations is defined as the minimum number of nucleotide mutations needed to generate any codon for that amino-acid. For a collection of sequences, we calculate the accessibility as the weighted average of the accessibilities of all codons observed at that site in the collection of sequences. Accessibility was calculated using code as documented here (<https://jbloomlab.github.io/dms_tools2/dms_tools2.utils.html?highlight=accessibility#dms_tools2.utils.codonEvolAccessibility>), in Jupyter notebook at <https://github.com/jbloomlab/PB2-DMS>, and in [Supplementary file 3](#supp3){ref-type="supplementary-material"}.

Quantification and statistical analysis {#s4-12}
---------------------------------------

Quantification and statistical analysis was performed in Python and a complete description is available in main text, methods, associated figure legends, and computational Jupyter notebooks.

Data and software availability {#s4-13}
------------------------------

Deep sequencing data have been deposited in the NCBI Sequence Read Archive under BioProject accession number PRJNA511556.

The GitHub repository <https://github.com/jbloomlab/PB2-DMS> contains Jupyter notebooks that perform all steps of computational analyses and provide detailed step-by-step explanations and plots. The README file explains the organization of the notebooks and other files. HTML renderings of the notebooks are provided in [Supplementary file 3](#supp3){ref-type="supplementary-material"}.
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The following dataset was generated:
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Comprehensive mapping of avian influenza polymerase adaptation to the human host\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Neil Ferguson as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Ervin Fodor (Reviewer \#1); Benjamin R. tenOever (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Soh et al. present an impressive amount of work and data analyses to comprehensively map residues on the PB2 polymerase subunit of influenza A virus that confer species adaptation. The results of this work provide a map for the most likely host adaptive mutations that might enable an avian influenza A virus strain to replicate efficiency in mammals. Their screens not only identified known PB2 variants involved in the transition from avian to mammalian adaptation, but they also identified a number of novel residues that confer comparable properties. Interestingly, they note that many of the residues implicated in mammalian adaptation fall adjacent to known sites of host interactions and are on the exposed surface of PB2. In addition, they found that those residues that increase transcriptional activity but have not been found in nature generally demand numerous nucleotide substitutions thus making their selection more difficult. Overall, this work is based on a beautiful combination of deep sequencing, functional experiments, correlation to known structural information and evolutionary analyses, and the results may provide an important resource to those trying to predict what strains to monitor from general viral surveillance efforts. Although the underlying mechanisms governing preference for certain amino acids at certain positions remain unexplored, the study is an important addition to the body of literature on the host adaptive changes of the influenza virus RNA polymerase.

Essential revisions:

1\) Figure 4. Please add statistical tests on the data in panels A, B, and C. For panel C, provide a more detailed description to help the reader to understand exactly what is plotted on the y-axis and how these data correspond with the two different MOIs used and total and viral RNA analyzed at 10 and 48 hpi (Subsection "Viral competition", second paragraph).

2\) Subsection "Human-adaptive mutations identified in deep mutational scanning improve polymerase activity and viral growth in human cells", fifth paragraph. Of the mutations that have little to no effect on polymerase activity, only R355G has a convincing effect in the viral competition assays. I292T, S523D, and to a lesser degree R355K do not deviate significantly from the starting ratio of wild type/mutant, especially when considering the E627E negative control. Hence the data do not support the conclusion that these mutations enhance viral growth.

3\) Subsection "Human-adaptive mutations cluster in regions of PB2 that are potentially important for host adaptation", first paragraph, Figure 5 and Figure 5---figure supplement 1. Top human-adaptive mutations appear to cluster in regions that play a role in host adaptation. It is not clear whether these are all surface exposed; were there any mutations affecting internal PB2 residues?

4\) Figure 6B. PB2 E627K is the most frequent adaptive mutation acquired by H7N9 influenza virus during avian-to-human transmission, but has a much lower differential selection than other less-frequent E627 mutations. Please address this apparent inconsistency.

5\) Saturating mutagenesis has already been performed at the two major sites of adaption, PB2 627 and 701 (Chin et al., 2014, and Chin et al., 2017, respectively). Differential selection for the PB2 pool in these prior experiments also found some of the same \"winners\" reported here. In addition, PB2 S627 has also been reported previously. This variant is naturally encoded by bat influenza viruses and supports high-level polymerase activity in human cells (Tong et al., 2012; Tong et al., 2013) Please reference and incorporate these points into your analysis.

6\) PB2 mutant viruses were rescued using a helper virus that encodes GFP in place of PB2. How is the PB2-like reporter gene eliminated from the mutant virus population, or does it persist? If it persists, how does the presence of what is effectively semi-infectious virus impact replication?

7\) The Discussion is very perfunctory and primarily repeats points already raised in the Results section. A synthesis of the current findings with the existing literature would help place these findings in context.

8\) Figure 2C-D: the authors don\'t comment on why the entropy in natural avian sequences is so much lower on average than in human sequences. As a non-expert this is what I noticed first about these panels. Perhaps this could be explained better in the text.

9\) Their minigenome assay (Figure 4A-B) is technically only a reporter assay for transcription and not necessarily replication, which they don\'t mention.

10\) Figure 4C, subsection "Human-adaptive mutations identified in deep mutational scanning improve polymerase activity and viral growth in human cells", fourth paragraph: viral competition assay. the authors say they infect both viruses at a 1:1 ratio, but how do they know it is actually a true 1:1 ratio? The Materials and methods state this is based on the IP/ul titer. This reviewer has no idea what that means as this is certainly not a conventional way of measuring virus. Moreover, how do the authors account for DIs etc.?

11\) Figure 5: I am not sure the authors have accounted for all of the published PB2 adaptations. A quick perusal on Pubmed identifies A44S, T105V, E158G, A199S, D253N, D256G, T271A, R368K, L475M, R493K, K526R, T559I, D567N, T569A, A588I, G590S, Q591R, V598T, V613T, A661T, A674T, G682S, A684S, and S714I as residues that have been implicated in avian-to-mammalian adaptation. Are the authors certain they are working off a comprehensive list of known adaptation residues? It seems incomplete.

10.7554/eLife.45079.037

Author response

> Essential revisions:
>
> 1\) Figure 4. Please add statistical tests on the data in panels A, B, and C. For panel C, provide a more detailed description to help the reader to understand exactly what is plotted on the y-axis and how these data correspond with the two different MOIs used and total and viral RNA analyzed at 10 and 48 hpi (Subsection "Viral competition", second paragraph).

We have now performed t-tests on panels A and B. We found that all mutations, except the ones we had previously noted as having little to no effect on polymerase activity, show significant effects (p \< 0.05). We have indicated significant differences with an asterisk (\*) on Figure 4A and B.

Experiments for Figure 4C were performed in biological duplicate, due to limitations on the number and scale of experiments. The duplicates do not provide enough statistical power to detect significant differences. However, the effects of mutations are evident by visual inspection of the two replicates, each of which were used in two independent infections and sampled at two different timepoints.

For Panel C, we have clarified in the figure itself and the text that the data plotted on the y-axis is the ratio of mutant:WT virus, in A549 over CCL-141 cells. We have also removed from the figure the connecting lines between the 10 hpi and 48 hpi datapoints, so as to clarify that the data at 10 hpi and 48 hpi are from separate infections with two different MOIs.

> 2\) Subsection "Human-adaptive mutations identified in deep mutational scanning improve polymerase activity and viral growth in human cells", fifth paragraph. Of the mutations that have little to no effect on polymerase activity, only R355G has a convincing effect in the viral competition assays. I292T, S523D, and to a lesser degree R355K do not deviate significantly from the starting ratio of wild type/mutant, especially when considering the E627E negative control. Hence the data do not support the conclusion that these mutations enhance viral growth.

We have now revised our description of the data to state that only R355G, and to a lesser degree R355K, have strong effects on viral growth among mutations that do not affect polymerase activity.

> 3\) Subsection "Human-adaptive mutations cluster in regions of PB2 that are potentially important for host adaptation", first paragraph, Figure 5 and Figure 5---figure supplement 1. Top human-adaptive mutations appear to cluster in regions that play a role in host adaptation. It is not clear whether these are all surface exposed; were there any mutations affecting internal PB2 residues?

Most of the sites of adaptive mutations are surface exposed in at least one of the two conformations of the polymerase. We have revised the text to clarify which sites are and are not surfaced exposed. We have also added an analysis of the relative solvent accessibility of these sites to Figure 5---figure supplement 1. Only mutations at sites 163 and 182 affect internal PB2 residues and are therefore not exposed in any known conformation of PB2. In addition, site 156, although on the surface of the PB2 protein, faces the internal core of the polymerase in both conformations examined, and is thus likely also inaccessible.

> 4\) Figure 6B. PB2 E627K is the most frequent adaptive mutation acquired by H7N9 influenza virus during avian-to-human transmission, but has a much lower differential selection than other less-frequent E627 mutations. Please address this apparent inconsistency.

We have added to the Discussion some possible reasons for inconsistencies between our deep mutational scanning measurements and the frequencies of mutations observed in nature. In particular, we address the reviewer's question of why the E627K mutation is most frequently observed in nature, though it has lower differential selection than other site 627 mutations. First, many mutations with higher differential selection than mutations we observe in nature are inaccessible from current avian influenza sequences by single-nucleotide mutations. This makes them much less likely to arise. Amongst mutations that are accessible by single-nucleotide mutations, such as E627K and E627V, the former is more frequently observed despite having lower differential selection. One possible explanation is that the rate of single-nucleotide mutations can differ depending on whether it is a transition or transversion. For example, the E627K mutation requires a transition from base G to A, whereas E627V requires a transversion from base A to T. Transitions occur at a higher rate than transversions. Specifically, previous measurements of influenza mutation rates estimates that G to A transitions occur at ten times the rate of A to T transversions. Finally, it is possible that other factors which are not captured by our in vitro model preferentially select for E627K.

> 5\) Saturating mutagenesis has already been performed at the two major sites of adaption, PB2 627 and 701 (Chin et al., 2014, and Chin et al., 2017, respectively). Differential selection for the PB2 pool in these prior experiments also found some of the same \"winners\" reported here. In addition, PB2 S627 has also been reported previously. This variant is naturally encoded by bat influenza viruses and supports high-level polymerase activity in human cells (Tong et al., 2012; Tong et al., 2013) Please reference and incorporate these points into your analysis.

We have revised the text to incorporate these references.

> 6\) PB2 mutant viruses were rescued using a helper virus that encodes GFP in place of PB2. How is the PB2-like reporter gene eliminated from the mutant virus population, or does it persist? If it persists, how does the presence of what is effectively semi-infectious virus impact replication?

The mutant virus library (still containing PB2-GFP gene segments) was passaged at very low MOI after rescue so as to purge any non-replicative virus, including those containing the GFP segment. We confirmed this by our observation that there is limited spread of GFP expression over the course of infection. We have now explained this in the Materials and methods section. During amplification of the PB2 gene segment for sequencing library preparation, we also observed that the band corresponding to full-length PB2 was generally more intense than the smaller bands likely corresponding to the PB2-GFP gene segment, as well as PB2 deletions, suggesting that full-length PB2 was the most prevalent. We suspect that the relative amounts of full-length PB2 could be even higher than indicated by the gel, as the product underwent 22 cycles of PCR, which is known to preferentially amplify shorter templates (such as PB2-GFP and PB2-deletions). We now provide this gel image as Figure 1---figure supplement 3.

> 7\) The Discussion is very perfunctory and primarily repeats points already raised in the Results section. A synthesis of the current findings with the existing literature would help place these findings in context.

We have now expanded our discussion of the current findings in context of existing literature. We explain how our complete map of adaptive mutations and amino acid preferences provides context for previously identified mutations that affect host adaptation and PB2 function. We explain that our analyses of new adaptive mutations in combination with previously identified mutations and published crystal structures suggest that host adaptation may involve mutations at sites at the periphery of core interactions. Finally, we also expand our discussion of why the magnitude of differential selection as quantified in our experiments do not always correspond to observed frequencies of mutations in nature that have been described in the literature, as explained in our response to comment 4 above.

> 8\) Figure 2C-D: the authors don\'t comment on why the entropy in natural avian sequences is so much lower on average than in human sequences. As a non-expert this is what I noticed first about these panels. Perhaps this could be explained better in the text.

We have now included an explanation in the text describing Figure 2. Entropy, a measure of sequence variation, is generally low in natural avian sequences, probably because influenza A virus is highly adapted to avian hosts so there is little pressure for additional adaptation. Entropy is generally higher in natural human sequences, likely because of increased genetic diversity generated as a result of directional selection to adapt to the human host (dos Reis et al., 2010), and diversifying selection to escape immune selection on PB2-derived T-cell epitopes (e.g. Assaarsson et al., 2008).

> 9\) Their minigenome assay (Figure 4A-B) is technically only a reporter assay for transcription and not necessarily replication, which they don\'t mention.

We have updated the text to emphasize that the minigenome assay only quantifies the transcription of mRNA by the viral polymerase.

> 10\) Figure 4C, subsection "Human-adaptive mutations identified in deep mutational scanning improve polymerase activity and viral growth in human cells", fourth paragraph: viral competition assay. the authors say they infect both viruses at a 1:1 ratio, but how do they know it is actually a true 1:1 ratio? The Materials and methods state this is based on the IP/ul titer. This reviewer has no idea what that means as this is certainly not a conventional way of measuring virus. Moreover, how do the authors account for DIs etc.?

We have now clarified that the IP/ul titer reflects transcriptionally active particles as determined by flow cytometry for HA expression in infected cells. We also clarify that cells were infected with a 1:1 ratio of transcriptionally active particles, to the best of our measurements. Our measurements of transcriptionally active particles includes potential DIs which are competent to infect and express HA, but are not necessarily fully infectious.

More importantly, as we clarify also in response to Comment 1, the data plotted in Figure 4C is the ratio of mutant:WT virus, in A549 over CCL-141 cells. So even if the ratio of mutant:WT infectious virus is not exactly 1:1, it is corrected for since we compare the ratio in two cell types. Therefore, the quantity on the y-axis is only sensitive to *relative* differences of the wildtype and mutant variants in the two cell types, not their exact ratio in any single cell type.

> 11\) Figure 5: I am not sure the authors have accounted for all of the published PB2 adaptations. A quick perusal on Pubmed identifies A44S, T105V, E158G, A199S, D253N, D256G, T271A, R368K, L475M, R493K, K526R, T559I, D567N, T569A, A588I, G590S, Q591R, V598T, V613T, A661T, A674T, G682S, A684S, and S714I as residues that have been implicated in avian-to-mammalian adaptation. Are the authors certain they are working off a comprehensive list of known adaptation residues? It seems incomplete.

We have double-checked and confirmed that most of the mutations listed above by the reviewer were included in our analyses. We did miss a few, which we have now included.

We now clarify that in Figure 5 we plot in blue adaptive mutations for which there is prior experimental support (total of 25 mutations). We also clarify that we have labeled only a select few of them as landmarks to refer to in the text. (There is not enough space to label all of them.)

We provide a full list of published PB2 mutations, both with and without prior experimental support, in Figure 3---source data 1. Our analyses use only those mutations which have been experimentally validated to improve polymerase activity or viral growth in a human or mammalian host. This is because some computationally identified host adaptive mutations have failed to experimentally validate (as reported in previous published studies). We also required that each mutation showed an adaptive effect on its own, rather than in combination with another adaptive mutation, so as to make a fair comparison to our experiments which aim to identify effects of single mutations.

Of the mutations listed above, the following were already included in our analyses as they have experimental support: T158G, A199S, D253N, D256G, T271A, K526R, A588I, Q591K, A684S.

Of the mutations listed above, the following were listed in Figure 3---source data 1, but were not used in our analyses as they are not yet supported by experimental evidence. We have repeated literature searches to confirm that there has been no new evidence since: A44S (did not improve polymerase activity when tested in Cauldwell et al., 2013), T105V, R368K (enhances pathogenicity only in combination with E627K), L475M, D567N, G590S (not yet tested separately from Q591R), Q591R (not yet tested separately from G590S), V613T, A661T, A674T (did not improve polymerase activity or viral replication alone, Lee et al., 2017), and G682S.

We did miss the following mutations: R493K, T559I, T569A, V598T, S714I. Of these, we found experimental support for only T569A. We found that S714I had been experimentally tested but showed rather modest effect (Czudai-Matwich et al., 2014). Another mutation at this same site, S714R was already included in our analyses as having experimental support. We have added these missed mutations to Figure 3---source data 1. We have also updated Figure 5 (as well as Figure 3) to include the one missed mutation with experimental support (T569A).
